Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
Christian MarthMiguel Henriques AbreuKlaus Kaae AndersenKaroliina M AroMaria de Lurdes BatardaDorry BollAnne Weng Ekmann-GadeUlla-Maija HaltiaJesper HansenAla Jabri HaugClaus HøgdallJacob KorachHeini LassusKristina LindemannEls Van NieuwenhuysenPetronella B OttevangerStephan PolterauerTine Henrichsen SchnackPublished in: Cancer (2022)
Patients with advanced (Stage III or IV) ovarian cancer (OC) have a poor prognosis. The standard treatment options of surgery and chemotherapy extend life beyond diagnosis for 5 years or more in only approximately 45% of patients. This study was aimed at describing the standard of care in eight Western countries and estimating how many patients who are diagnosed with high-grade serous or endometrioid OC could potentially be eligible for first-line poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) maintenance therapy. The results highlight the poor prognosis for these patients and suggest that a significant proportion (79%) would potentially be eligible for first-line PARPi maintenance treatment.
Keyphrases
- poor prognosis
- end stage renal disease
- high grade
- ejection fraction
- long non coding rna
- newly diagnosed
- chronic kidney disease
- peritoneal dialysis
- minimally invasive
- machine learning
- metabolic syndrome
- squamous cell carcinoma
- randomized controlled trial
- adipose tissue
- patient reported outcomes
- south africa
- coronary artery disease
- cross sectional
- coronary artery bypass
- chronic pain
- percutaneous coronary intervention
- insulin resistance